Related Experiment Video

Updated: May 11, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

13 years of trabectedin, 5 years of Yondelis®: what have we learnt?

Axel Le Cesne1

  • 1Medicine Department, Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France. lecesne@igr.fr

Expert Review of Anticancer Therapy
|May 4, 2013
PubMed

Insights

Trabectedin demonstrates prolonged tumor control in advanced soft tissue sarcoma, offering a favorable safety profile compared to traditional chemotherapy. Its unique efficacy in specific sarcoma subtypes suggests a paradigm shift in treatment strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Sarcoma Research

Background:

  • Advanced soft tissue sarcomas often exhibit resistance to anthracycline and ifosfamide treatments.
  • Trabectedin represents a novel therapeutic agent investigated for refractory sarcoma cases.
  • The unique response patterns observed with trabectedin necessitate re-evaluation of efficacy assessment criteria.

Purpose of the Study:

  • To evaluate the efficacy and safety of trabectedin in patients with advanced soft tissue sarcoma.
  • To explore the potential of trabectedin in achieving prolonged tumor control.
  • To investigate the suitability of trabectedin for specific sarcoma subtypes, particularly translocation-related sarcomas.

Main Methods:

  • Review of clinical trial data for trabectedin in advanced soft tissue sarcoma.
  • Analysis of response patterns and safety profiles compared to conventional agents.
  • Exploration of trabectedin's efficacy in translocation-related sarcoma subtypes.

Main Results:

  • Trabectedin shows promise for prolonged tumor control in advanced soft tissue sarcoma.
  • The drug exhibits a more favorable safety profile than doxorubicin and ifosfamide, with less neutropenia and alopecia.
  • Efficacy in translocation-related sarcomas suggests a targeted treatment approach.

Conclusions:

  • Trabectedin is a promising agent for anthracycline/ifosfamide-resistant sarcomas.
  • The drug's unique efficacy and safety profile may alter the standard of care for advanced soft tissue sarcoma.
  • Further research and ongoing clinical trials are expected to solidify trabectedin's role in sarcoma treatment.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...